(Circulation. 2004;110:3506-3508.)
© 2004 American Heart Association, Inc.
Editorial |
From the Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of CaliforniaLos Angeles.
Correspondence to Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, 47123 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-1679. E-mail gfonarow@mednet.ucla.edu
Key Words: Editorials heart failure trials lifestyle patients
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Heart failure (HF) remains a major public health problem that affects 5 million patients in the United States.1 HF is the leading cause of hospitalization for people 65 years of age and older, and rates of hospital readmission within 6 months range from 25% to 50%.1,2 The personal burden of HF includes debilitating symptoms, frequent rehospitalizations, and high rates of mortality.2 HF also poses a substantial economic burden, with annual direct costs for the care of HF patients estimated to be between $20 billion and $56 billion.13 A number of studies have documented marked variation in the quality of care judged by specific performance measures and substantial underuse of evidence-based, guideline-recommended HF therapies in patients receiving conventional care.2,4,5 Moreover, patient behavioral factors (such as nonadherence to diet and medications) and economic and social factors frequently contribute to rehospitalizations.2,5,6 The traditional model of care delivery is thought to contribute to frequent hospitalizations because in these brief episodic encounters, little attention may be paid to the common modifiable factors that precipitate many hospitalizations.6 As such, there has been much interest in identifying effective methods to improve the quality of care for HF patients while reducing costs.
See p 3518
We and others first studied the use of comprehensive HF management programs involving specialty care and a multidisciplinary team; the goals of the HF disease management (DM) programs included optimization of drug therapy, intensive patient education, vigilant follow-up with early recognition of problems, and identification and management of patients comorbidities.79 HF patients who
Related Article:
Circulation 2004 110: 3518-3526.
This article has been cited by other articles:
![]() |
B. K. Nallamothu, R. A. Hayward, and E. R. Bates Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies Circulation, September 16, 2008; 118(12): 1294 - 1303. [Full Text] [PDF] |
||||
![]() |
J. E. Sisk, P. L. Hebert, C. R. Horowitz, M. A. McLaughlin, J. J. Wang, and M. R. Chassin Effects of Nurse Management on the Quality of Heart Failure Care in Minority Communities: A Randomized Trial Ann Intern Med, August 15, 2006; 145(4): 273 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Casalino Disease Management and the Organization of Physician Practice JAMA, January 26, 2005; 293(4): 485 - 488. [Full Text] [PDF] |
||||
![]() |
J. G.F. Cleland Patients with treatable malignant diseases -- including heart failure -- are entitled to specialist care Can. Med. Assoc. J., January 18, 2005; 172(2): 207 - 209. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |